Amisulpride – an underrated drug with many faces Case report
Article Sidebar
Published:
Dec 31, 2024
Keywords:
amisulpride, neuroleptic, schizophrenia
Main Article Content
Abstract
Although amisulpride is one of the earliest neuroleptics introduced in psychiatry, its pharmacological properties and differentiated dose-dependent effects mean that it can be still used in various clinical situations. New off-label reimbursement indications, i.e. F21, F22, F23, F24, F25, F28, F29 according to ICD-10, enable a wider use of the drug, but for this to be possible it is necessary to understand its mechanism of action. In this article, we recall several basic facts about amisulpride and present several clinical cases showing the use of different doses depending on the symptom profile and clinical picture of the disease at a given time.
Article Details
How to Cite
Antosik-Wójcińska, A., & Antoniak, B. (2024). Amisulpride – an underrated drug with many faces. Medycyna Faktow (J EBM), 17(4(65), 551-555. https://doi.org/10.24292/01.MF.0424.18
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. World Psychiatric Association. History of the World Psychiatric Association.
2. Hadrys T, Rymaszewska J. Amisulpryd – lek taki sam jak wszystkie czy inny? Aktualizacja. Psychiatr Pol. 2020; 54(5): 977-89.
3. Łoza B. Amisulpryd: szerokie spektrum zastosowań klinicznych. Neuropsychiatria. 2017; 9 (1): 18-23.
4. Charakterystyka produktu leczniczego. Metoclopramid. 18.08.2023.
5. Charakterystyka produktu leczniczego. Tiapryd. 31.08.2023.
6. Psychofarmakologa kliniczna. Rybakowski J (ed). PZWL, Warszawa 2022.
7. Rzewuska M. Amisulprid w leczeniu chorych na schizofrenię – podsumowanie danych, 2008. Farmakoter Psychiatr Neurol. 2008; 24(4): 227-42.
8. McKeage K, Plosker GL. Amisulpride: A review of its use in the management of schizophrenia. CNS Drugs. 2004; 18(13): 933-56.
9. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951-62.
10. Bergemann N, Kopitz J, Kress KR et al. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur. Neuropsychopharmacol. 2004; 14(3): 245-50.
11. Charakterystyka produktu leczniczego. Amisulpryd. 05.2023.
12. Urichuk L, Prior TI, Dursun S et al. Metabolism of atypical antipsychotics: Involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008; 9(5): 410-8.
13. Amore M, Jori MC. Amisert investigators. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: A randomized, double-blind, parallel group study. Int Clin Psychopharmacol. 2001; 16(6): 317-24.
14. Lecrubier Y, Boyer P, Turjanski S et al. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord. 1997; 43(2): 95-103.
15. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord. 1998; 48(1): 47-56.
16. Ravizza L; AMILONG investigators. Amisulpride in mediumterm treatment of dysthymia: A six-month, double-blind safety study versus amitriptyline. J Psychopharmacol. 1999; 13(3): 248-54.
17. Boyer P, Lecrubier Y, Stalla-Bourdillon A et al. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology. 1999; 39(1): 25-32.
18. Rocca P, Fonzoa V, Ravizzaa L et al. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Dis. 2002; 70(3): 313-7.
19. Bogorni F, Moreira FF, Pimentel EM et al. Amisulpride Augmentation for Clozapine-Refractory Positive Symptoms: Additional Benefit in Reducing Hypersialorrhea. Case Rep Psychiatry. 2015; 2015: 408179.
20. Genç Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther. 2007; 24(1): 1-13.
21. Zink M, Knopf U, Henn FA et al. Combination of clozapine and amisulpride in treatment-resistant schizophrenia-case reports and review of the literature. Pharmacopsychiatry. 2004; 37(1): 26-31.
22. Dudek D. Zespół metaboliczny u pacjentów ze schizofrenią. Wybrane problemy kliniczne. Forum Zaburzeń Metabolicznych. 2010; 1(3): 123-30.
2. Hadrys T, Rymaszewska J. Amisulpryd – lek taki sam jak wszystkie czy inny? Aktualizacja. Psychiatr Pol. 2020; 54(5): 977-89.
3. Łoza B. Amisulpryd: szerokie spektrum zastosowań klinicznych. Neuropsychiatria. 2017; 9 (1): 18-23.
4. Charakterystyka produktu leczniczego. Metoclopramid. 18.08.2023.
5. Charakterystyka produktu leczniczego. Tiapryd. 31.08.2023.
6. Psychofarmakologa kliniczna. Rybakowski J (ed). PZWL, Warszawa 2022.
7. Rzewuska M. Amisulprid w leczeniu chorych na schizofrenię – podsumowanie danych, 2008. Farmakoter Psychiatr Neurol. 2008; 24(4): 227-42.
8. McKeage K, Plosker GL. Amisulpride: A review of its use in the management of schizophrenia. CNS Drugs. 2004; 18(13): 933-56.
9. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951-62.
10. Bergemann N, Kopitz J, Kress KR et al. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur. Neuropsychopharmacol. 2004; 14(3): 245-50.
11. Charakterystyka produktu leczniczego. Amisulpryd. 05.2023.
12. Urichuk L, Prior TI, Dursun S et al. Metabolism of atypical antipsychotics: Involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008; 9(5): 410-8.
13. Amore M, Jori MC. Amisert investigators. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: A randomized, double-blind, parallel group study. Int Clin Psychopharmacol. 2001; 16(6): 317-24.
14. Lecrubier Y, Boyer P, Turjanski S et al. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord. 1997; 43(2): 95-103.
15. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord. 1998; 48(1): 47-56.
16. Ravizza L; AMILONG investigators. Amisulpride in mediumterm treatment of dysthymia: A six-month, double-blind safety study versus amitriptyline. J Psychopharmacol. 1999; 13(3): 248-54.
17. Boyer P, Lecrubier Y, Stalla-Bourdillon A et al. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology. 1999; 39(1): 25-32.
18. Rocca P, Fonzoa V, Ravizzaa L et al. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Dis. 2002; 70(3): 313-7.
19. Bogorni F, Moreira FF, Pimentel EM et al. Amisulpride Augmentation for Clozapine-Refractory Positive Symptoms: Additional Benefit in Reducing Hypersialorrhea. Case Rep Psychiatry. 2015; 2015: 408179.
20. Genç Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther. 2007; 24(1): 1-13.
21. Zink M, Knopf U, Henn FA et al. Combination of clozapine and amisulpride in treatment-resistant schizophrenia-case reports and review of the literature. Pharmacopsychiatry. 2004; 37(1): 26-31.
22. Dudek D. Zespół metaboliczny u pacjentów ze schizofrenią. Wybrane problemy kliniczne. Forum Zaburzeń Metabolicznych. 2010; 1(3): 123-30.